Key result
Combined 3D body measurements and biomarker scores identify CAD with an AUC of ~0.80.
Why the study?
The relationship between three-dimensional scanning-derived body surface measurements and biomarkers in patients with coronary artery disease was not defined.
Do 3D body surface measurements combined with biomarkers predict the presence of coronary artery disease in adults?
Cross-Sectional (n=196)
No
Do 3D body surface measurements combined with biomarkers predict the presence of coronary artery disease in adults?
Effect estimate: AUC 0.8049 (95% CI 0.7440-0.8657)
p-value: p=<0.0001
The combination of 3D anthropometric body surface measurements and specific biomarkers (leptin, adiponectin, IL6) provides a non-invasive and accurate method for identifying patients at high risk for coronary artery disease.
Background and Objectives: The relationship between three-dimensional (3D) scanning-derived body surface measurements and biomarkers in patients with coronary artery disease (CAD) were assessed. Methods and Methods: The recruitment of 98 patients with CAD confirmed by cardiac catheterization and 98 non-CAD patients were performed between March 2016 and December 2017. A health questionnaire on basic information, life style variables, and past medical and family history was completed. 3D body surface measurements and biomarkers were obtained. Differences between the two groups were assessed and multivariable analysis performed. Results: It was found that chest width (odds ratio [OR] 0.761, 95% confidence interval [CI] = 0.586–0.987, p = 0.0399), right arm length (OR 0.743, 95% CI = 0.632–0.875, p = 0.0004), waist circumference (OR 1.119, 95% CI = 1.035–1.21, p = 0.0048), leptin (OR 1.443, 95% CI = 1.184–1.76, p = 0.0003), adiponectin (OR 0.978, 95% CI = 0.963–0.994, p = 0.006), and interleukin 6 (OR 1.181, 95% CI = 1.021–1.366, p = 0.0254) were significantly associated with CAD. The combination of biomarker scores and body measurement scores had the greatest area under the curve and best association with CAD (area under the curve of 0.8049 and 95% CI = 0.7440–0.8657). Conclusions: Our study suggests that 3D derived body surface measurements in combination with leptin, adiponectin, and interleukin 6 levels may direct us to those at risk of CAD, allowing a non-invasive approach to identifying high-risk patients.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2023) conducted a cross-sectional in Coronary Artery Disease (n=196). 3D body surface measurements and biomarkers vs. Non-CAD controls was evaluated on Presence of coronary artery disease (combination of biomarker and body measurement scores) (AUC 0.8049, 95% CI 0.7440-0.8657, p=<0.0001). The combination of 3D-derived body surface measurement scores and biomarker scores (leptin, adiponectin, and interleukin 6) was strongly associated with coronary artery disease, yielding an AUC of 0.8049.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: